by Carolyn Y. Johnson, The Boston Globe
Leonard Freedman, chief executive of the nonprofit Global Biological Standards Institute, which is trying to find ways to improve the quality of biomedical research, said that the problem is likely getting greater attention because of a recent push for translational research that aims to bring basic research closer to the lives of real people.
“The public is much more aware of what’s going on,” Freedman said. When the studies are “so much closer to a clinical candidate or a clinical trial, the stakes are really much higher.”